CAT
Caterpillar Inc.
CAT has the edge over RRX overall, supported by stronger modeled upside and stronger fundamentals.
RRX
Regal Rexnord Corporation
RRX's outlook is improving despite an expensive valuation.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
RRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Under pressure |
RRX's revenue, profitability and cash flow are currently stable, but its balance sheet is under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT has the edge over RRX in the historical PE scenario, which offers more potential upside but is not a forecast.
RRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $181 | — |
| Cheap | 21x | $72.73 | -60% |
| Fair | 28x | $96.42 | -47% |
| Expensive | 42x | $145 | -19% |
| Current | 52x | $181 | — |
Historical ranges are pointers, not guarantees.
RRX's PE is in its expensive range at 52x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
RRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for RRX, with profitability improving. However, they disagree widely on these estimates.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
RRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.07 | +249% |
| Q3 2026 | $3.46 | -10% |
| Q2 2026 | $4.85 | +29% |
| Q1 2026 | $4.30 | +23% |
| Q4 2025 | $4.20 | +43% |
| Q3 2025 | $3.86 | +22% |
| Q2 2025 | $3.75 | +$3.77 |
| Q1 2025 | $3.50 | +$3.98 |
| Q4 2024 | $2.94 | +$3.81 |
RRX has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over RRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over RRX on profitability, with a higher operating margin.
RRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +6.1% |
| Q2 2026 | $1.6B | +4.2% |
| Q1 2026 | $1.5B | +4.3% |
| Q4 2025 | $1.5B | +4.3% |
| Q3 2025 | $1.5B | +1.3% |
| Q2 2025 | $1.5B | -3.3% |
| Q1 2025 | $1.4B | -8.4% |
| Q4 2024 | $1.5B | -9.1% |
RRX's revenue has grown year over year for five quarters in a row: $1.6B last quarter, up 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.1% | -6.5 points |
| Q2 2026 | 14% | +1.6 points |
| Q1 2026 | 10% | -0.9 points |
| Q4 2025 | 11% | +2 points |
| Q3 2025 | 12% | -0.1 points |
| Q2 2025 | 12% | -0.3 points |
| Q1 2025 | 11% | +2.6 points |
| Q4 2024 | 8.8% | -2.2 points |
RRX's operating margin was 5.1% last quarter, down 6.5 points from the same quarter a year ago, near the bottom of its range since 2019.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
RRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $193.7M | +11% |
| Q2 2026 | $154.2M | -69% |
| Q1 2026 | -$2.5M | -103% |
| Q4 2025 | $140.6M | -24% |
| Q3 2025 | $174M | +39% |
| Q2 2025 | $493M | +292% |
| Q1 2025 | $85.5M | +32% |
| Q4 2024 | $183.9M | +7.6% |
RRX has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over RRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
RRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -300K shares |
| 1 year | 0% | -- |
| 3 years | +0.5% | +300K shares |
| 5 years | +62% | +25.6M shares |
| Available history | +62% | +25.5M shares |
RRX has 67M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | $55.2M |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over RRX on leverage, with a lower net debt burden relative to earnings.
RRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.6x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 4.0x | Elevated |
| Q1 2025 | 4.3x | High |
| Q4 2024 | 4.4x | High |
RRX's net debt is about 3.6 years of its operating earnings (EBITDA), down from 3.8 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
RRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.7 | Neutral |
| Stochastic | 43.2 | Neutral |
RRX's weekly RSI is 53 (neutral) and its Stochastic is 43 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT has the edge over RRX on valuation relative to its sector.
RRX PE vs Industrials Sector
| Metric | RRX | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 24x | 117% above |
| PE % | 97 | 58 | 39 pts above |
RRX is trading at 52x earnings, a 117% premium to the Industrials sector's median of 24x.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
RRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $161.2 | 12% above |
| 20 week MA | $174.9 | 3.2% above |
| 50 week MA | $183.1 | 1.4% below |
| 100 week MA | $160.9 | 12% above |
| 200 week MA | $155.4 | 16% above |
RRX has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
RRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.4 | $120.2 | +41% |
| 2021 | $120.2 | $165.2 | +37% |
| 2022 | $165.2 | $118.6 | -28% |
| 2023 | $118.6 | $148.0 | +25% |
| 2024 | $148.0 | $156.5 | +5.7% |
| 2025 | $156.5 | $145.2 | -7.2% |
| 2026 YTD | $145.2 | $180.5 | +24% |
RRX has the edge over CAT on returns for 2026, with the stronger performance.